Neopharm Ltd Stock Return On Asset
| 092730 Stock | KRW 11,950 10.00 0.08% |
NeoPharm LTD fundamentals help investors to digest information that contributes to NeoPharm's financial success or failures. It also enables traders to predict the movement of NeoPharm Stock. The fundamental analysis module provides a way to measure NeoPharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NeoPharm stock.
NeoPharm |
NeoPharm LTD Company Return On Asset Analysis
NeoPharm's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current NeoPharm Return On Asset | 0.11 |
Most of NeoPharm's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NeoPharm LTD is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, NeoPharm LTD has a Return On Asset of 0.1067. This is much higher than that of the Personal Products sector and significantly higher than that of the Consumer Staples industry. The return on asset for all Republic of Korea stocks is notably lower than that of the firm.
NeoPharm Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NeoPharm's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NeoPharm could also be used in its relative valuation, which is a method of valuing NeoPharm by comparing valuation metrics of similar companies.NeoPharm is currently under evaluation in return on asset category among its peers.
NeoPharm Fundamentals
| Return On Equity | 13.82 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 153.58 B | |||
| Shares Outstanding | 7.99 M | |||
| Shares Owned By Insiders | 38.94 % | |||
| Shares Owned By Institutions | 17.81 % | |||
| Price To Earning | 42.54 X | |||
| Price To Sales | 1.56 X | |||
| Revenue | 87.93 B | |||
| Gross Profit | 58.64 B | |||
| EBITDA | 24.3 B | |||
| Net Income | 17.71 B | |||
| Cash And Equivalents | 7.05 B | |||
| Total Debt | 101.79 M | |||
| Debt To Equity | 0.60 % | |||
| Current Ratio | 4.20 X | |||
| Book Value Per Share | 4,777 X | |||
| Cash Flow From Operations | 21.68 B | |||
| Earnings Per Share | 576.00 X | |||
| Target Price | 36000.0 | |||
| Number Of Employees | 106 | |||
| Beta | 1.11 | |||
| Market Capitalization | 156.02 B | |||
| Total Asset | 143.41 B | |||
| Retained Earnings | 19.71 B | |||
| Working Capital | 16.77 B | |||
| Current Asset | 22.83 B | |||
| Current Liabilities | 6.06 B | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 143.41 B |
About NeoPharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NeoPharm LTD's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeoPharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeoPharm LTD based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with NeoPharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeoPharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeoPharm will appreciate offsetting losses from the drop in the long position's value.Moving against NeoPharm Stock
The ability to find closely correlated positions to NeoPharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeoPharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeoPharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeoPharm LTD to buy it.
The correlation of NeoPharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeoPharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeoPharm LTD moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NeoPharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in NeoPharm Stock
NeoPharm financial ratios help investors to determine whether NeoPharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NeoPharm with respect to the benefits of owning NeoPharm security.